OSE Immunotherapeutics Names Marc Le Bozec Interim CEO Following Board Decision To Conclude Nicolas Poirier’s CEO Mandate

OSE Immunotherapeutics has announced changes in its executive management. The company’s Board of Directors has decided to end the role of Nicolas Poirier as Chief Executive Officer and has appointed Marc Le Bozec as interim CEO, a decision that was finalized during the Board meeting held yesterday. The Board has already initiated a formal search to identify and appoint a new permanent Chief Executive Officer. Until then, Marc Le Bozec will oversee the company’s operations and lead a strategic review of OSE’s activities, with particular focus on partnerships, financial resources, and ongoing clinical development programs.

Nicolas Poirier will remain with the company as Chief Scientific Officer, continuing his contributions in research and innovation. The conclusion of his CEO role will not involve any compensation or indemnity, since he is employed and remunerated under his existing employment contract with OSE. The compensation terms for the future permanent Chief Executive Officer will be evaluated by the Nomination and Compensation Committee and presented for approval at the next shareholders’ general meeting, as the company does not currently have a defined compensation policy for this position.

Dr. Markus Cappel, Chairman of the Board of Directors, welcomed the appointment of Marc Le Bozec, expressing confidence in his leadership. He emphasized the importance of reassessing the company’s current position, realigning its strategic direction, and accelerating its progress during this transitional phase. He noted that Marc Le Bozec’s strong background in the French and international biotech sector, along with his governance and investment management expertise, would bring stability, re-engage stakeholders, and help unlock OSE’s potential.

In his remarks, Marc Le Bozec thanked the Board for its trust and highlighted his priorities as interim CEO. He stressed that OSE is at a turning point and requires a comprehensive review to ensure sustainable growth and value creation for shareholders. He also underlined the importance of providing reassurance and clear direction to employees while maintaining therapeutic innovation at the core of the company’s mission.

Marc Le Bozec brings significant experience in the biotech sector. He currently advises several biotech companies as a consultant, board member, and investor, with a strong track record in interim management. Between 2015 and 2023, he created and managed two biotech investment funds at Financière Arbevel, completing 11 investments and achieving successful exits with TransCure bioServices, acquired by Cathay Capital in 2022, and Imactis, acquired by GE Healthcare in 2023. 

Prior to that, he served as Chief Financial Officer of Cellectis, where he raised €120 million and prepared the company for its Nasdaq listing. He also restructured CYTOO successfully. Earlier in his career, he founded BioProtein Technologies in 1998 and held consulting roles at Bossard Consultants and Arthur D. Little in organizational and strategy consulting. He is a graduate of HEC Paris (1992).